José Ramón Azanza1, Santiago Grau2, Lourdes Vázquez3, Pablo Rebollo4, Carmen Peral5, Alejandra López-Ibáñez de Aldecoa5, Vanessa López-Gómez6. 1. Clinical Pharmacology Department, Clínica Universidad de Navarra, Pamplona, Spain. 2. Pharmacy Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Hematology Department, Hospital Clínico Universitario de Salamanca, Salamanca, Spain. 4. Ingress-health, Oviedo, Spain. 5. Pharmacoeconomics Department, Pfizer, Madrid, Spain. 6. Medical Department, Pfizer, Madrid, Spain.
Abstract
BACKGROUND: Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin-B is not indicated. OBJECTIVES: To estimate the cost-effectiveness of isavuconazole vs voriconazole for the treatment of adult patients with possible IA prior to differential pathogen diagnosis, in Spain. METHODS: A decision tree analysis was performed using the Spanish Healthcare System perspective. Among all patients with possible IA, it was considered that 7.81% actually had IM. Costs for laboratory analysis, management of adverse events, hospitalisation and drugs per patient, deaths and long-term effects in life years (LYs) and quality-adjusted LYs (QALYs) were considered. Efficacy data were obtained from clinical trials and utilities from the literature. Deterministic and probabilistic sensitivity analyses (PSA) were conducted. RESULTS: In patients with possible IA and when compared to voricanozole, isavuconazole showed an incremental cost of 4758.53€, besides an incremental effectiveness of +0.49 LYs and +0.41 QALYs per patient. The Incremental Cost Effectiveness Ratio was 9622.52€ per LY gained and 11,734.79€ per QALY gained. The higher cost of isavuconazole was due to drug acquisition. Main parameters influencing results were mortality, treatment duration and hospitalisation days. The PSA results showed that isavuconazole has a probability of being cost-effective of 67.34%, being dominant in 24.00% of cases. CONCLUSIONS: Isavuconazole is a cost-effective treatment compared to voriconazole for patients with possible IA for a willingness to pay threshold of 25,000€ per additional QALY.
BACKGROUND: Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin-B is not indicated. OBJECTIVES: To estimate the cost-effectiveness of isavuconazole vs voriconazole for the treatment of adult patients with possible IA prior to differential pathogen diagnosis, in Spain. METHODS: A decision tree analysis was performed using the Spanish Healthcare System perspective. Among all patients with possible IA, it was considered that 7.81% actually had IM. Costs for laboratory analysis, management of adverse events, hospitalisation and drugs per patient, deaths and long-term effects in life years (LYs) and quality-adjusted LYs (QALYs) were considered. Efficacy data were obtained from clinical trials and utilities from the literature. Deterministic and probabilistic sensitivity analyses (PSA) were conducted. RESULTS: In patients with possible IA and when compared to voricanozole, isavuconazole showed an incremental cost of 4758.53€, besides an incremental effectiveness of +0.49 LYs and +0.41 QALYs per patient. The Incremental Cost Effectiveness Ratio was 9622.52€ per LY gained and 11,734.79€ per QALY gained. The higher cost of isavuconazole was due to drug acquisition. Main parameters influencing results were mortality, treatment duration and hospitalisation days. The PSA results showed that isavuconazole has a probability of being cost-effective of 67.34%, being dominant in 24.00% of cases. CONCLUSIONS:Isavuconazole is a cost-effective treatment compared to voriconazole for patients with possible IA for a willingness to pay threshold of 25,000€ per additional QALY.
Authors: Julio López-Bastida; Juan Oliva; Fernando Antoñanzas; Anna García-Altés; Ramón Gisbert; Javier Mar; Jaume Puig-Junoy Journal: Eur J Health Econ Date: 2010-04-20
Authors: Emma Bagshaw; Daniel Kuessner; Jan Posthumus; Cesar Escrig; Michael Blackney; Sebastian Marcel Heimann; Oliver Andreas Cornely Journal: Future Microbiol Date: 2017-02-13 Impact factor: 3.165
Authors: A Xhaard; F Lanternier; R Porcher; E Dannaoui; A Bergeron; L Clement; C Lacroix; R Herbrecht; F Legrand; M Mohty; M Michallet; C Cordonnier; S Malak; D Guyotat; L J Couderc; G Socié; N Milpied; O Lortholary; P Ribaud Journal: Clin Microbiol Infect Date: 2012-06-04 Impact factor: 8.067
Authors: J Peter Donnelly; Sharon C Chen; Carol A Kauffman; William J Steinbach; John W Baddley; Paul E Verweij; Cornelius J Clancy; John R Wingard; Shawn R Lockhart; Andreas H Groll; Tania C Sorrell; Matteo Bassetti; Hamdi Akan; Barbara D Alexander; David Andes; Elie Azoulay; Ralf Bialek; Robert W Bradsher; Stephane Bretagne; Thierry Calandra; Angela M Caliendo; Elio Castagnola; Mario Cruciani; Manuel Cuenca-Estrella; Catherine F Decker; Sujal R Desai; Brian Fisher; Thomas Harrison; Claus Peter Heussel; Henrik E Jensen; Christopher C Kibbler; Dimitrios P Kontoyiannis; Bart-Jan Kullberg; Katrien Lagrou; Frédéric Lamoth; Thomas Lehrnbecher; Jurgen Loeffler; Olivier Lortholary; Johan Maertens; Oscar Marchetti; Kieren A Marr; Henry Masur; Jacques F Meis; C Orla Morrisey; Marcio Nucci; Luis Ostrosky-Zeichner; Livio Pagano; Thomas F Patterson; John R Perfect; Zdenek Racil; Emmanuel Roilides; Marcus Ruhnke; Cornelia Schaefer Prokop; Shmuel Shoham; Monica A Slavin; David A Stevens; George R Thompson; Jose A Vazquez; Claudio Viscoli; Thomas J Walsh; Adilia Warris; L Joseph Wheat; P Lewis White; Theoklis E Zaoutis; Peter G Pappas Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079
Authors: José Ramón Azanza; Santiago Grau; Lourdes Vázquez; Pablo Rebollo; Carmen Peral; Alejandra López-Ibáñez de Aldecoa; Vanessa López-Gómez Journal: Mycoses Date: 2020-10-30 Impact factor: 4.377